Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Bayer

Podcast 1: Upper GI

Dr Efrat Dotan and Dr Nataliya Uboha focus on their selected key abstracts in upper GI cancer, sharing their thoughts on how the data could influence the treatment and management of gastric/gastro-esophageal (G/GE) cancer.

Clinical takeaways: 

  • SPOTLIGHT trial results demonstrate the benefit of treatment with zolbetuximab + mFOLFOX in patients expressing Claudin 18.2  
  • In RATIONALE 305, tislelizumab, like nivolumab, shows promising results for PD-L1+ve patients
  • CheckMate 649 follow up data at 3 years further supports the use of nivolumab + chemotherapy in first-line setting in patients with advanced G/GE cancer
  • INTEGRATE IIa study had statistically significant results for regorafenib vs placebo in refractory advanced GE cancer. Results of INTEGRATE IIb are eagerly awaited 
  • The data from NEO-AEGIS make clinical decision-making between peri-operative chemotherapy and CROSS easier
  • The results from INFINITY show the potential of tremelimumab + durvalumab as standard of care for patients with resectable MSI-H G/GE cancer

 

Podcast 2: Lower GI 

Prof. Shubham Pant and Prof. Andrea Sartore-Bianchi discuss lower GI cancer and the key abstracts that they identified as potentially impacting the way we manage treatment for colorectal cancer (CRC).

Clinical takeaways:

  • In SUNLIGHT, trifluridine/tipiracil plus bevacizumab improved overall survival and progression-free survival in refractory CRC patients and should be considered a standard of care in the refractory treatment setting
  • In the kinetics of postoperative cfDNA/ctDNA2 study, post operative ctDNA-positivity was significantly associated with shorter recurrence-free survival. Clinical data are insufficient at this stage to consider molecular residual disease testing as standard of care for patients with resectable CRC
  • Durable objective responses were observed in heavily pre-treated MSS CRC patients treated with balstilimab plus botensilimab. Further investigation is warranted
  • In NRG-GI002, neither veliparib or pembrolizumab significantly improved short-term outcomes in unselected patients when added to total neoadjuvant therapy (TNT). This trial provides TNT outcome data for benchmarking in future LARC trials

 

Listen to the podcasts and download the slides on the selected abstracts.

 

Ass. Prof. Efrat Dotan is an Assistant Professor of Medical Oncology at Fox Chase Cancer Center, in Philadelphia. She graduated from the Technion Institute of Technology Medical School in Israel and moved to the US to pursue her specialized training. She completed her residency at Lenox Hill Hospital in New York, and her hematology/oncology fellowship at Fox Chase Cancer Center. Ass. Prof. Dotan specializes in the management of patients with gastrointestinal malignancies, specifically pancreatic cancer. Her research interest is in development of new treatment options for patients with gastrointestinal cancers. She is the PI for multiple clinical trials in this arena. Ass. Prof. Dotan is a member of the Gastrointestinal Malignancies Committee of the Eastern Cooperative Oncology Group (ECOG) and serves as the PI for multiple studies. She also serves as a member of the Pancreatic Cancer Guideline Panel for the National Comprehensive Cancer Network (NCCN). Dr Dotan’s other interest is in the management of older patients with cancer, and tools to improve the care of this patient population. She has led multiple research projects evaluating the care of older patients with gastrointestinal malignancies. She is a senior member of the Cancer and Aging Research Group, and the chair of the Older Adult Oncology Guidelines for NCCN.

Asst. Prof. Efrat Dotan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research grants/clinical trials paid to the institution: Eli Lilly, Gilead, Lutris, Zymworks, Relay, Ipsen, AstraZeneca, MedImmune, Incyte
Honorarium: Pfizer, Incyte, Helsinn, Taiho, G1 Therapeutics

Dr Nataliya Uboha is an Associate Professor at the University of Wisconsin, Department of Medicine, Division of Hematology and Oncology and a member of Carbone Cancer Center (UWCCC). Her clinical and research activities focus on upper GI cancers. She has extensive clinical trial experience, with a particular emphasis on phase 1 and biomarker based clinical studies. She is a Faculty Leader for the Cancer Therapy Discovery & Development (Phase I) Program at UWCCC. She is a co-leader and founder of the Basket Disease Oriented Team at UWCCC, which has a specific focus on biomarker based trials across disease types. Dr Uboha has a number of regional and national leadership roles. She serves on the board of Wisconsin Association of Hematology and Oncology. She is a co-chair for the GI Cancer Research Group in Big 10 Cancer Research Consortium. She chairs the Upper GI working group at ECOG-ACRIN and serves on the National Cancer Institute Upper GI Taskforce as an ECOG representative.

Dr Nataliya Uboha has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting: QED, Taiho Inc., Incyte, AstraZeneca, Pfizer, Boston Gene, Helsinn
Research Funding: Taiho Inc, Ipsen, EMD Serono
Long position holdings: Natera, Exact Sciences

Prof. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. He previously served as the Director of Clinical Trials for the Section of Hematology-Oncology and Associate Director of the Tobacco Settlement Endowment Trust (TSET) Phase 1 program, for the Stephenson Cancer Center in Oklahoma City. Furthermore Prof. Pant was the Oncology Lead of the Clinical Research Disease Site Group for Gastrointestinal Cancers and Clinical Research Disease Site Group Chair for Hepatocellular Cancers at the same institute. Prof. Pant completed his fellowship from the Ohio State University, where he was elected Chief Fellow. He previously served as an elected member at large to the Board of Directors for Cancer and Leukemia Group B (CALGB), was the Site Principal Investigator for CALGB and was a Member of the Board of Trustees for ACTION. Prof. Pant served on the Board of Oklahoma Society of Clinical Oncology. He is a participant in the ASCO Leadership Development Program, Class of 2015-16. His awards include the Golden Pillar Award for Outstanding Patient Service in 2012 and 2014, America’s Top Doctors by Castle Connolly and Oklahoma 40 Under 40 in the Oklahoma Magazine. In 2015, he anchored a health show on CNN-IBN India titled: ‘Let’s Talk Health’.

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or advisory Role: Zymeworks, Ipsen, Novartis, Janssen, AskGene Pharma, BPGBio, Jazz, AstraZeneca, Boehringer Ingelheim, USWorldmeds, Nihon Medi-Physics Co, Ltd, Alligator Bioscience, Theriva Biosciences.

Research funding (funding to institution): Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol-Myers Squibb, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Pharmaceuticals, Janssen, Arcus, Elicio, Biontech, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics.

Dr Andrea Sartore-Bianchi is head of Clinical Molecular Oncology at the Department of Hematology & Oncology, Niguarda Cancer Center, Milano, Italy. He completed his medical degree at the University of Pavia in 1999, and undertook specialist training at IRCCS Policlinico San Matteo. After completing his doctoral studies, he conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics in the Department of Medicine at Brown University, Rhode Island, USA. Dr Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-II-III clinical trials for gastrointestinal malignancies, and first author of research articles in the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and PLoS One. Currently, he is adjunct Professor for the School of Specialization in Oncology and Pharmacology at the University of Milano. He has been listed among the top 30 authors of primary research papers on cancer.

Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bayer, Sanofi and Servier Pharmaceuticals. 

Programme summary
Other episodes in this series
Update from ASCO GI 2023

Update from ASCO GI 2023

Episode 1: Upper GI cancer highlights

Update from ASCO GI 2023

Update from ASCO GI 2023

Episode 2: Lower GI highlights

Current Episode
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer and BeiGene Europe.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.